Also Read | India speeds up vaccination driveInstead of requiring tens of thousands of volunteers and costing several hundred million dollars, such trials could involve only hundreds of people at a fraction of the cost.
They could be used to speed the availability of new vaccines targeting emerging variants.Moderna Inc., Pfizer and its partner BioNTech SE, and a federally funded network of researchers are conducting analyses to learn what immune response is necessary for protection with current vaccines, known as an immune correlate of protection.